Saturday, September 14, 2024
9/14/2024
PROJECT SUMMARY: Cardiovascular disease is a leading cause of death, and mitochondrial dysfunction is implicated in the pathogenesis of cardiomyopathy. Cardiac troponin I (cTnI) is a regulator of myocyte contraction, and mutations in cTnI lead to hypertrophic, dilated, and restrictive cardiomyopathies and sudden death. It is not known why cTnI mutations have such heterogeneous phenotypes, and there are no targeted therapies for cardiomyopathies caused by cTnI mutations. cTnI is regulated by phosphorylation and proteolytic truncation. We recently showed that selectively inhibiting phosphorylation of cTnI by delta protein kinase C (δPKC) during myocardial infarction using a lab-designed peptide inhibitor attenuates cardiac injury and prevents mitochondrial dysfunction. My preliminary data show a novel role of cTnI in inhibiting mitochondrial function, and a therapeutic benefit of preventing cTnI’s binding to mitochondrial ATP synthase using a peptide inhibitor in ischemic injury. The objective of this application is to identify the mechanisms by which cTnI inhibits mitochondrial function and to define the interplay between cTnI mutations and mitochondrial dysfunction in genetic cardiomyopathies. My central hypothesis is that cTnI phosphorylation and truncation directly inhibit mitochondrial function, and mutations in cTnI impair mitochondrial function to cause cardiomyopathy. This hypothesis will be tested in two specific aims: 1) Determine the effect of cTnI phosphorylation and truncation on mitochondrial function and 2) determine the effect of pathogenic cTnI mutations on mitochondrial function. In Aim 1, I will test the effect of recombinant cTnI with phospho-mimetic amino acid substitutions and N-terminal truncation on ATP synthase binding/activity and mitochondrial respiration. I will also express phospho-mimetic cTnI and N-terminal truncated cTnI in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) to examine their effects on mitochondrial structure/function and myocyte contractility/relaxation kinetics. In Aim 2, I will use hiPSC-CM and transgenic mice with cTnI mutations to establish the effect of pathogenic mutations (causing hypertrophic, dilated and restrictive cardiomyopathy) on mitochondrial function and test the effect of lab-designed peptide inhibitors of cTnI phosphorylation and mitochondrial binding on mitochondrial function and contractility/relaxation in vivo. This research is expected to identify a novel and therapeutically targetable role of cTnI in inhibiting mitochondrial function and exacerbating myocardial remodeling in genetic cardiomyopathies. To successfully complete this project, Dr. Elezaby’s educational goals include training in 1) rational drug design; 2) hiPSC-CM biology; 3) genotype-specific mechanisms in genetic cardiomyopathies; 4) scientific communication; and 5) professional development. His mentorship team includes world-renowned experts in mitochondrial and stem cell biology, drug development, myocyte physiology, and cardiovascular genetics. His career development plan has been designed to ultimately achieve his long-term goal of becoming a leading clinician-scientist investigating the mechanistic underpinnings, therapeutic targets, and interplay between cardiac metabolism and cardiomyopathy.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
